Crohn’s Disease is Associated with an Increased Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study using Magnetic Resonance Proton Density Fat Fraction Mapping.

Related Articles Crohn’s Disease is Associated with an Increased Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study using Magnetic Resonance Proton Density Fat Fraction Mapping. Clin Gastroenterol Hepatol. 2019 Mar 12;: Authors: McHenry S, Sharma Y, Tirath A, Tsai R, Mintz A, Fraum TJ, Salter A, Browning JD, Flores AG, Davidson NO, Fowler KJ, Ciorba MA, Deepak P PMID: 30876963 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30876963?dopt=Abstract

Read More

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis.

Related Articles Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019 Mar 12;: Authors: Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ Abstract BACKGROUND & AIMS: We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF targeted biologics, tofacitinib, and immunosuppressive agents in patients with inflammatory bowel diseases (IBD). METHODS: In a systematic search of publications, through March 18, 2018,…

Read More

Clinical Practice Guideline for the Management of Luminal Crohn’s Disease: The Toronto Consensus.

Related Articles Clinical Practice Guideline for the Management of Luminal Crohn’s Disease: The Toronto Consensus. Clin Gastroenterol Hepatol. 2019 Mar 07;: Authors: Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN Abstract BACKGROUND & AIMS: Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms…

Read More

Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines.

Related Articles Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines. Clin Gastroenterol Hepatol. 2019 Mar 07;: Authors: Khan N, Lee H, Trivedi C, Kavani H, Medvedeva E, Xie D, Lewis JD, Yang YX Abstract BACKGROUND & AIMS: Treatment with thiopurines is associated with an increased risk of squamous cell carcinoma of the skin (SCC) in patients with inflammatory bowel diseases (IBD). We studied outcomes of patients with IBD who developed SCC while receiving thiopurine therapy. METHODS: We conducted a retrospective…

Read More

Patients Who Undergo Colectomy for Pediatric Ulcerative Colitis at Low-volume Hospitals Have More Complications.

Related Articles Patients Who Undergo Colectomy for Pediatric Ulcerative Colitis at Low-volume Hospitals Have More Complications. Clin Gastroenterol Hepatol. 2019 Mar 07;: Authors: Egberg MD, Galanko JA, Kappelman MD Abstract BACKGROUND & AIMS: Adults with ulcerative colitis (UC) who undergo colectomy at high-volume centers have better outcomes and fewer complications than those at low-volume centers. We aimed to evaluate hospital volume of total abdominal colectomy (TAC) for pediatric patients with UC and explore time trends in the proportion of colectomies performed at high-volume centers. We then evaluated the association between…

Read More

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease.

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Mar 06;: Authors: Soufflet N, Boschetti G, Roblin X, Cuercq C, Williet N, Charlois AL, Duclaux-Loras R, Danion P, Mialon A, Faure M, Paul S, Flourie B, Nancey S PMID: 30851477 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30851477?dopt=Abstract

Read More

Association Between Level of Fecal Calprotectin and Progression of Crohn’s Disease.

Association Between Level of Fecal Calprotectin and Progression of Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 Feb 14;: Authors: Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW Abstract BACKGROUND & AIMS: Mucosal healing is associated with improved outcomes in patients with Crohn’s disease (CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to determine luminal disease activity in place of endoscopy-this measurement is an important component of the treat to target strategy. We investigated whether levels of fecal calprotectin associate with subsequent CD…

Read More
<< Go Back